TPX-0131

brain-penetrant mutant ALK kinase inhibitor

oral, Ph. I/II in ALK+ pre-treated cancers

undisclosed starting point, SBDD

Molecular Cancer Therapeutics

Turning Point Therapeutics, San Diego, US

2. The Turning Point Therapeutics CNS-penetrant ALK kinase inhibitor, TPX-0131, is more potent in vitro than all 5 approved ALK inhibitors against WT-ALK and many ALK resistance mutations, including…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks